Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series)

Wolfgang M. Kuebler1, Sébastien Bonnet2 and Arata Tabuchi1

1Charité Universitätsmedizin Berlin Institut für Physiologie, Berlin, Germany; 22725 Chemin St Foy, Quebec, QC, Canada

Abstract
While pulmonary hypertension (PH) has traditionally not been considered as a disease that is directly linked to or, potentially, even caused by inflammation, a rapidly growing body of evidence has demonstrated the accumulation of a variety of inflammatory and immune cells in PH lungs, in and around the wall of remodeled pulmonary resistance vessels and in the vicinity of plexiform lesions, respectively. Concomitantly, abundant production and release of various inflammatory mediators has been documented in both PH patients and experimental models of PH. While these findings unequivocally demonstrate an inflammatory component in PH, they have fueled an intense and presently ongoing debate as to the nature of this inflammatory aspect: is it a mere bystander of or response to the actual disease process, or is it a pathomechanistic contributor or potentially even a trigger of endothelial injury, smooth muscle hypertrophy and hyperplasia, and the resulting lung vascular remodeling? In this review, we will discuss the present evidence for an inflammatory component in PH disease with a specific focus on the potential role of the endothelium in this scenario and highlight future avenues of experimental investigation which may lead to novel therapeutic interventions.

Keywords
pulmonary hypertension, inflammation, endothelium, adhesion molecules

Inflammatory cells and mediators in pulmonary hypertension
Specific subclasses of pulmonary arterial hypertension (PAH) have traditionally been linked to inflammation and immunity due to the inflammatory or infectious nature of their underlying or associated disease. Prototypic examples are PAH forms related to connective tissue diseases such as systemic sclerosis or lupus erythematosus, but also PAH as a consequence of HIV infection or related to other viral etiologies. The implication of inflammation and immunity in pulmonary hypertension (PH), however, is much older, and seems to reach far beyond these most striking associations.

Already in 1878, when Paul Ehrlich identified the mast cell, he reported that these cells were most abundant in “brown induration of the lung,” i.e. in hemosiderosis, which we nowadays would classify as type II PH, i.e. PH following left heart disease. Subsequent clinical studies confirmed the accumulation of mast cells in lungs of patients with idiopathic PAH (iPAH) or “secondary” PAH (which nowadays would be considered associated PAH) or in patients with PH owing to mitral stenosis and left heart disease. Measurements of mast cell densities in lungs of native highlanders revealed that mast cell numbers were only increased in subjects with considerable muscularization of their pulmonary circulation, indicating a functional role for mast cells in lung vascular remodeling.

These clinical findings were paralleled by reports of similar mast cell accumulations in experimental models of PH, notably in chronic hypoxic rats as well as calves, pigs, and sheep, in the rat monocrotaline model of PH, in rat
models of left heart disease, or in a combined model of monocrotaline and left-to-right shunt. More recently, the recognition of immune cell abundance and infiltration in lung vascular lesions and remodeled vessels has expanded profusely (Fig. 1): innate immune cells such as macrophages and monocytes are characteristically detected in patients with iPAH, in PH secondary to congenital cardiac shunts and in murine and rat lungs in response to chronic hypoxia or monocrotaline. Vascular lesions and the adventitial space of remodeled blood vessels in iPAH patients and monocrotaline-induced experimental PH are also infiltrated by immature dendritic cells. In addition to infiltrating innate immune cells, the adaptive immune response has recently become implicated in PH based on the fact that perivascular accumulations of B cells have not only been documented in PAH associated with connective tissue disorders or HIV infection, but also in plexiform lesions of patients with iPAH, as well as in experimental PH. Work by the groups of Perros et al. and Colvin et al. has identified the formation of characteristic tertiary lymphoid tissue comprising B- and T-cell areas with high endothelial venules and dendritic cells in the vicinity of remodeled pulmonary arteri(ol)es and bronchi(oles) in iPAH patients as well as animal models of PH.

This infiltration of innate and adaptive immune cells is associated with—and likely orchestrated by—the activation of several key transcription factors such as the nuclear factor of activated T cells (NFAT) and STAT3 contributing to the release of numerous cytokines. Patients with iPAH or associated PAH exhibit higher circulating levels and/or pulmonary expression of tumor necrosis factor (TNF), interleukins (IL) including IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13, and a series of chemokines including fractalkine (CX3CL1), RANTES (CCL5), monocyte chemotactic protein-1 (MCP-1; CCL2), and interferon γ-induced protein 10 (IP-10; CXCL10). Of the characteristic cytokines, IL-6 seems of particular relevance in the context of PH as suggested by experimental studies and biomarker screenings: in PAH patients, plasma IL-6 levels predict five-year survival with a higher prognostic accuracy as functional or hemodynamic parameters. Similarly, circulating IL-6 in PAH patients contribute to the development of co-morbidities in PAH such as coronary artery diseases through the activation of the Bromodomain-containing protein 4 (BRD4), while increased TNF contributes to right ventricular failure through a miR-208/myocyte enhancer factor 2 (MEF2)-dependent mechanism. The importance of circulating cytokines especially IL-6 is reinforced by the fact that lung-specific overexpression of IL-6 in mice suffices to cause elevated right ventricular systolic pressures and right ventricular hypertrophy with corresponding pulmonary vascular changes. Conversely, IL-6-deficient mice develop less PH, right ventricular hypertrophy, and lung vascular

Fig. 1. Infiltration of inflammatory and immune cells into the wall and perivascular space of pulmonary arteries in PH. A schematic cross-section shows a pulmonary artery with its different layers (intima, media, and adventitia) and the characteristic accumulation of inflammatory and immune cells, namely macrophages, dendritic cells, T cells, B cells, mast cells, and plasma cells, as well as the infiltration of fibroblasts and myofibroblasts and the production of (auto-)antibodies in PH disease.
remodeling in chronic hypoxia compared to their corresponding IL-6+/− wild type (WT). In addition to classic inflammatory cytokines, immune responses in PH may also be triggered or aggravated by other pro-inflammatory mediators such as leukotrienes (LTs) or complement factors. Recent studies suggest an important role for LTB4 in the context of immune dysregulation in PAH. LTs are lipid mediators derived from arachidonic acid. Following activation of 5-lipoxygenase (5-LO) by 5-LO-activating protein (FLAP), arachidonic acid is converted to LTA4, an unstable epoxide which is subsequently further metabolized by either LTA4 hydrolase or LTC4 synthase to LTB4 or LTC4, respectively. In rats exposed to chronic hypoxia, expression levels of 5-LO and FLAP are increased in alveolar macrophages and endothelial cells, and in athymic rats treated with the VEGF receptor antagonist SU5416, which develop lethal PH even under normoxic conditions, LTB4 levels were found to be elevated in bronchoalveolar lavage fluid and serum. Analogously in PAH patients, alveolar macrophages expressing 5-LO and FLAP are more frequently clustered in the vicinity of remodeled blood vessels, while endothelial cells in plexiform and concentric lesion similarly express both enzymes.

Pharmacological antagonization of 5-LO and FLAP by MK-866 was shown to prevent hypoxic pulmonary vasoconstriction and development of chronic hypoxia-induced PH, thus establishing a functional role of LTs in PH.

LTB4 exerts its chemoattractant and pro-inflammatory effects predominantly via its high affinity receptor BLT1 which is widely expressed on immune cells including granulocytes, T cells, and dendritic cells. In vitro, LTB4 induces apoptosis of pulmonary artery endothelial cells via a signaling pathway that involves spingosine kinase 1 and endothelial nitric oxide synthase, and stimulates proliferation of human pulmonary artery smooth muscle cells, which is effectively blocked by the BLT-1 inhibitor U75302. In addition, LTB4 may further promote PH by stimulating proliferation, migration, and differentiation of pulmonary arterial adventitial fibroblasts. In vivo, inhibition of LTB4 formation by the LTA4 hydrolase inhibitor Ubenimex rescued PH rats from death. In PAH patients, LTA4 hydrolase expression was shown to be increased in CD68+ macrophages clustered around occluded vascular lumens of plexiform lesions, and circulating levels of LTB4 were found to be elevated in PAH patients with connective tissue disease though not in iPAH. From these studies, LTB4 has emerged as an important inflammatory signal and, hence, also potential drug target in PH. In respect to the latter, the recent completion of the LIBERTY trial, a phase 2 study on the effectiveness of the LTA4 hydrolase inhibitor Ubenimex in patients with PAH (LIBERTY:NCT02664558), is expected to provide key insight into the therapeutic potential of this pathway.

Considering that complement factors C3 and C4a have been identified as biomarkers of iPAH, it is surprising that the functional role of the complement system as a critical regulator of innate and adaptive immune responses in PH has thus far scarcely been addressed. In what is to our knowledge the only mechanistic study so far, Bauer et al. were able to demonstrate increased deposition of the C3 degradation product C3d in the pulmonary vessel wall in a murine PH model of chronic hypoxia and in human iPAH patients. More importantly, C3-deficient mice developed less PH with no increase in pulmonary IL-6 or tissue factor, less P-selectin on platelets, and less pulmonary intercellular adhesion molecule 1 (ICAM-1) expression during chronic hypoxia compared to WT mice, suggesting that C3 plays an important role in the pathophysiology of PH, potentially by promoting inflammatory cell interaction and recruitment via adhesion molecules such as P-selectin and ICAM-1. Since various novel therapies targeting the complement system are presently tested in clinical trials, the functional role of the complement system in PH and its therapeutic exploitation pose intriguing topics for future research.

The functional relevance of immune responses in the initiation and/or progression of PH has recently become evident, in that pharmacological inhibition, depletion, or genetic deficiency in specific cell subsets such as mast cells or B cells has been shown to confer protection from the development of PH in a variety of animal models. Furthermore, IL-6 has been identified as a critical link between mast cells and B cells and, hence, between the innate and adaptive immune system in that mast cell-derived IL-6 promotes the formation of tertiary lymphoid tissue in PH lungs in line with previous data demonstrating that mast cells synthesize and release IL-6. Originally identified as a B cell stimulatory factor that induces differentiation into antibody-producing plasma cells, IL-6 production has also been linked to increased Ig secretion and production of autoantibodies. A similar and potentially parallel pathway linking mast cells to B cells may act via another member of the IL-6 family, the pleiotropic cytokine oncostatin M. Like IL-6, OSM is also secreted by mast cells and upregulated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and scleroderma or in plasma of PAH patients. Endotracheal administration of an adenoviral vector expressing mouse oncostatin M promotes B cell activation and formation of tertiary lymphoid tissue independent of IL-6, suggesting that mast cells may regulate adaptive (auto-)immunity and formation of tertiary lymphoid tissue via different pathways in PH.

Importantly, the emerging role of mast cells, B cells, and other inflammatory cells in PH is not a purely theoretical concept but of tremendous translational potential and, as such, has already reached the clinical setting. Mast cell stabilizers have been shown to reduce inflammation and increase exhaled NO in PAH patients in a small pilot study, while a clinical phase II trial on the effect of the B cell depleting anti-CD20 antibody rituximab for the treatment of systemic sclerosis-associated PAH is currently underway (NCT01086540). Care should, however,
be taken with respect to existing immunosuppressive drugs, as poor safety profiles and potentials for drug–drug interactions with current PH therapies may present dangerous pitfalls for their implementations in clinics.68

While mast cells and B cells promote the development of PH, CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells (T regs), a subpopulation of T cells which maintains tolerance to self-antigens and downregulates autoimmune disease, seem to attenuate experimental PH. Athymic mice or rats lacking T cells characteristically develop more severe PH in response to monocrotaline or SU5416 compared to euthymic rodents.69,70 The beneficial effect of T regs in PH was particularly evident in a study in athymic rats in that the development of lung vascular remodeling and PH in response to SU5416 was attenuated in animals that had been reconstituted with CD4<sup>+</sup>CD25<sup>+</sup> T regs.71 This may at first seem contradictory, as B cells are considered to maintain72 and expand73–76 T regs. Conversely however, a series of animal studies on autoimmune diseases show that depletion of B cells causes activation and proliferation of T regs which are associated with marked improvement of histological or functional parameters of disease severity.77–79 The clinical relevance of this scenario is highlighted by the fact that B cell depletion with rituximab restores T reg numbers in peripheral blood of patients with immune thrombocytopenia (ITP), an effect that is particularly evident in therapy responders.80 Conversely, B cells may thus potentially promote inflammatory (auto-)immune responses by inhibiting T regs.

The differential involvement of innate and adaptive immune cells, the temporal sequence of their infiltration, their mutual crosstalk, and interdependency are exciting topics of ongoing and future research in PH of which the interaction between mast cells and B cells via cytokines of the IL-6 family as outlined above may only serve as prototypical example. At present, our insight into the individual mechanisms that trigger adaptive versus innate immune responses in PH is rudimentary, as is our understanding regarding their differential potential as therapeutic targets in PH. While an exhaustive discussion of this topic is beyond the scope of this manuscript, the dissection of innate and adaptive immune responses in PH clearly deserves deeper exploration in terms of experimental studies and state-of-the-art reviews.

**Autoimmunity in pulmonary hypertension**

The recognition of B cell activation and tertiary lymphoid tissue formation has recently fueled the intriguing hypothesis of a relevant autoimmune component in the pathogenesis and/or pathophysiology of PH. This view is supported by genomic analyses which identified a distinct RNA expression profile in peripheral blood B cells, indicative of their activation in patients with iPAH compared to healthy controls.81 Notably, while differentiation of B cells to antibody-producing plasma cells was originally considered to be restricted to lymph nodes,82 the recent recognition of functional ectopic lymphoid tissues adjacent to remodeled vessels in lungs of patients with iPAH clearly demonstrates that B cell differentiation and subsequent antibody production can occur and may be regulated at the local level in PH lungs.83 Many of these ectopic lymphoid tissues form germinal centers where somatic hypermutation and class-switching occur, thereby providing an optimal environment for the generation of pathogenic autoantibodies.83

Formation of autoantibodies has long been recognized as a key factor that is assumed to account for the high prevalence of PAH in patients with connective tissue diseases (CTDs) such as systemic sclerosis84,85 or Sjögren’s syndrome86 where antibody deposits have been found localized in the pulmonary artery walls.87,88 However, the presence of tertiary lymphoid tissue in patients with iPAH as well as in various animal models of hypoxia- or monocrotaline-induced PH suggests a much broader relevance of autoimmunity in the pathogenesis of PAH. Along these lines, increased levels of various circulating autoantibodies have been detected in patients with non-CTD PAH: It is estimated that 10–15% of iPAH patients are positive for antiphospholipid antibodies,89 30–40% express antinuclear antibodies,90,91 40% anti-fibroblast antibodies,92 62% anti-endothelial cell antibodies,93,94 and up to 93% anti-fibrillin-I antibodies.95 In recent collaborative work, we furthermore identified the prevalence of circulating agonistic autoantibodies against endothelin receptor type A (ET<sub>A</sub>R) and the angiotensin receptor type-1 (AT<sub>1</sub>R), which not only predicted the development of PAH and PAH-associated mortality in patients with systemic sclerosis, but were also present in 11% and 21% of patients with iPAH, respectively.96 The functional relevance of these autoantibodies was recently elegantly demonstrated, in that passive transfer of either autoantibody-rich plasma or purified immunoglobulin (Ig) G from rats with monocrotaline-induced PH was sufficient to induce the de novo formation of lung ectopic lymphoid tissue and the development of PH in naïve rats.97 Notably, increased production of autoantibodies does not seem to be restricted to PAH patients or the monocrotaline model of PH, as increased levels of circulating immunoglobulin G were similarly detected in a rat model of PH with left heart disease,98 in which moreover immunoglobulin-encoding genes were found to be the most mast cell-dependent regulated genes in lung tissue.99 While these findings point to an overarching relevance of pathogenic autoantibodies in the development of PH that is not restricted to CTDs, the mechanisms that drive this acquired autoimmunity remain unclear.

Autoimmunity emerges when the fragile balance between self-recognition and protection from non-self-pathogens is lost.99 It has been estimated that 50–75% of newly produced human B cells are autoreactive and must be eliminated by tolerance mechanisms.99 This B cell tolerance is established at multiple checkpoints throughout B cell development, both in the bone marrow and in the periphery by
mechanisms such as receptor editing, clonal deletion, and anergy, which serve to eliminate autoreactive B cells.\textsuperscript{100–102} The actual development of autoimmunity is driven via the activation of distinct pro-inflammatory signaling pathways, which have accordingly emerged as potential novel therapeutic targets for individual autoimmune diseases, including transcription factors such as STAT4,\textsuperscript{103} cytokines such as interleukin-17,\textsuperscript{104} or alarmins such as high mobility group box 1 (HMGB1).\textsuperscript{105–107} HMGB1 gains particular relevance as a potential link between inflammation/autoimmunity and pulmonary vascular disease through its recent implication in both clinical and preclinical PAH. HMGB1 is abundant both in serum and in vascular lesions of patients with iPAH,\textsuperscript{108,109} and the increase in circulating HMGB1 correlates with mean pulmonary artery pressure.\textsuperscript{108} Evidence for a functional role of HMGB1 in PAH comes from rodent models of chronic hypoxia and monocrotaline, respectively, where treatment with anti-HMGB1 antibodies attenuated the development of PH\textsuperscript{108,110} as did a non-specific inhibitor of HMGB1, glycyrrhizin.\textsuperscript{111} Notably, the fact that actively secreted HMGB1 is primarily derived from macrophages\textsuperscript{112} provides an intriguing link to a series of recent publications which attribute a key role for macrophages in the initiation of PAH.\textsuperscript{113–117} Indeed, remodeled vessels in lung samples of patients with iPAH are often surrounded by HMGB1-positive cells in the adventitia\textsuperscript{109} where perivascular macrophages accumulate in PAH.\textsuperscript{118} Of particular relevance in the context of autoimmunity, extracellular HMGB1 in isolation or in complex with DNA promotes the proliferation and activation of autoreactive B cells.\textsuperscript{119–121} Consistent with this view, autoantibody production was recently found to correlate with HMGB1 serum levels in patients with systemic lupus erythematosus.\textsuperscript{122} Conversely, blockade of extracellular HMGB1 suppresses xenoreactive B cell responses, autoantibody production, and delays acute vascular rejection following heterotopic heart xenotransplantation.\textsuperscript{123} Additionally, HMGB1, as a part of DNA-anti-DNA immune complexes, can interact with the receptor for advanced glycation endproducts (RAGE) on the surface of plasmacytoid dendritic cells and B cells leading to TLR9-dependent interferon-\(\alpha\) release and activation of autoreactive B cells.\textsuperscript{124} The latter aspect may be of particular relevance in the context of PH as RAGE activation is increased in PAH patients and systemic vascular diseases.\textsuperscript{125,126} Thus, HMGB1 emerges as a potent trigger and promoter of autoimmunity via both direct and indirect effects on B cells and as a trigger or promoter of vascular remodeling in PH; yet although it is tempting to postulate a functional link between these two effects a direct causal interrelationship remains to be shown.

**The endothelium in inflammation and immunity**

What remains obscure and has not been addressed in either preclinical or clinical studies so far is the origin of these inflammatory and immune cells in PH, and the mechanisms that trigger and regulate their recruitment to the lung parenchyma and into the vicinity of the remodeling pulmonary blood vessels. At later stages of the disease, some of these cells may expand locally within the tissue and the newly formed lymphoid tissues, yet it seems fair to assume that at least initially the inflammatory cells infiltrate the lung largely from the circulating blood. This notion is supported, for example, by flow cytometric analyses in chronic hypoxic mice demonstrating the mobilization of cells positive for the mast cell (and stem cell) marker c-kit from the bone marrow into the circulation and their subsequent accumulation in remodeled pulmonary artery vessel walls.\textsuperscript{127,128} In neonatal rats and calves, development of chronic pulmonary hypertension required the recruitment of a monocyte/macrophage precursor from the circulating blood into the pulmonary perivascular space.\textsuperscript{129} Similarly, flow cytometric analyses in various organs of rats with monocrotaline-or SU5416/hypoxia-induced PH revealed an increase in B cells abundance in virtually all organs including lung, lymph nodes, spleen, and circulating blood with the notable exception of bone marrow.\textsuperscript{26}

It remains unclear whether the inflammatory and immune cells that migrate into the lungs in PH are recruited directly from the pulmonary arteries or arterioles, from the vasa vasorum and the perivascular capillary network,\textsuperscript{130} or from the lymphatic vasculature. That notwithstanding, the recruitment will have to occur along the lines of the classic leukocyte adhesion and migration cascade that has been extensively studied and described in the past (Fig. 2). In brief, in order for circulating leukocytes to leave the blood stream and enter the perivascular space and the lung parenchyma, they first need to interact, adhere, and ultimately migrate through the vascular (or, alternatively, lymphatic) endothelium in a tightly controlled sequence of events.\textsuperscript{131,132} This cascade comprises initial steps of tethering and rolling, followed by firm arrest and occasional crawling along the vessel wall until the inflammatory cell exits the vessel by ways of paracellular or, occasionally, transcellular migration. The sequential steps of this adhesion cascade are mediated by the interaction of adhesion molecules expressed on the vascular endothelium with their respective counterligands on circulating leukocytes or platelets that may in turn form aggregates with leukocytes.\textsuperscript{133} In what has become known as the classic paradigm of the leukocyte adhesion cascade, leukocytes first start to role via the interaction of leukocytic L-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) with P- and E-selectin expressed on the vascular endothelium, and may subsequently adhere via CD11a/CD18 (lymphocyte function-associated antigen 1, LFA-1) or CD11b/CD18 (macrophage-1 antigen, Mac-1) interacting with ICAM-1, or integrin \(\alpha_{\beta_1}\) (very late antigen-4, VLA-4) interacting with vascular cell adhesion protein 1 (VCAM-1) (Fig. 3). This general concept applies not only for neutrophils, but equally for migrating mast cells,\textsuperscript{134,135} B cells,\textsuperscript{136} and monoclonal cells.\textsuperscript{137} While the
exact molecular players that orchestrate this sequence will vary between different vascular beds and leukocyte subsets, it is a fundamental paradigm that each of these steps is mediated by the intimate interaction of adhesion molecules expressed on the infiltrating leukocyte on the one, and the vessel outlining endothelium on the other hand. With that in mind it must come as a surprise that so far no clinical or preclinical studies have to our knowledge...
addressed the role of specific adhesion molecules in PH, either by pharmacological or antibody blockade or by genetic deletion strategies. There is, however, an abundance of studies that have reported elevated levels of circulating soluble adhesion molecules in PH patients. As such, marked increases in the plasma concentration of soluble P-selectin have been detected in PAH patients with either idiopathic or non-idiopathic disease. Similarly, patients with PH due to left heart disease have been found to exhibit higher circulating levels of soluble P-selectin, although this finding did not reach significance, and P-selectin expression on platelets as an indicator of their activation is increased in patients with chronic thromboembolic pulmonary hypertension (CTEPH). In patients with congenital heart disease (CHD), P-selectin genotype polymorphism of -825T/C differs significantly between patients with and without PH, suggesting a potential contributory role of the P-selectin genotype in the development of PH in this patient population. Circulating levels of soluble P-selectin did, however, not correlate with World Health Organization functional class (FC) or transplant-free survival in a recent biomarker study in 65 PAH patients, and were not associated with changes in 6-min walk distance or FC in response to PAH therapy by treprostinil.

For soluble E-selectin, elevated levels have been reported in iPAH patients compared to healthy controls. Likewise, soluble intercellular adhesion molecule-1 (ICAM-1) levels in serum are significantly higher in children with PH secondary to CHD compared to children with CHD without associated PAH, or in a healthy control group. ICAM-1 levels are also increased in iPAH patients and patients with PAH associated with connective tissue disease (PAH-CTD), whereas circulating levels of soluble vascular cell adhesion protein 1 (VCAM-1) were elevated in PAH-CTD only. Conversely, soluble ICAM-1 levels decreased when young patients with CHD and PH were treated with the phosphodiesterase 5 inhibitor sildenafil. Interestingly, ICAM-1 expression on pulmonary arterial but not microvascular endothelial cells can be increased when endothelial cells are exposed to microparticles isolated from PH rats. In line with their proposed role as disseminators of inflammatory cells adhering to the endothelium, P-selectin is stimulated by most of the classic triggers of endothelial instability as previously detected in pulmonary arterial hypertension. P-selectin shows enhanced adhesiveness for monocytes in response to inflammatory mediators, yet this concept remains to be experimentally tested. As important endothelial shear sensor, increased cleavage of PECAM-1 from the endothelial surface may not only result in elevated levels of circulating soluble PECAM-1, but also impair microvascular adaptation to shear and thus, promote the development of occlusive vascular lesions in PAH.

In addition to analyses of circulating soluble adhesion molecules, a few studies have addressed the expression of endothelial adhesion molecules in human tissue samples or primary endothelial cells, respectively. As such, Venethasamy et al. showed that pulmonary microvascular endothelial cells isolated from lungs of transplanted PAH patients show an elevated ICAM-1 expression in BMPR2 mutation carriers compared to patients without mutations. Consistent with this finding, pulmonary microvascular endothelial cells from BMPR2 mutation carriers showed an enhanced adhesiveness for monocytes in response to inflammatory mediators, suggesting that BMPR2 mutations could increase the susceptibility to inflammatory cell recruitment in PAH. In line with these data, Le Hiress et al. detected an increased expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin on the endothelium of pulmonary arteries in human iPAH compared to controls that was associated with a higher number of peripheral blood mononuclear cells adhering to the endothelium.

Taken together, these studies at large demonstrate an association of increased levels of circulating or endothelial adhesion molecules with PH, whereby the individual adhesion molecules may vary based on severity, time course, or underlying cause/class of the disease. Expectedly, adhesion molecule expression correlates with leukocyte interaction with the pulmonary endothelium in PH; importantly, however, experiments on the functional role of adhesion molecules in PH in vivo are to our knowledge lacking as of now.

The potential triggers of endothelial inflammation and adhesion molecule expression in PH are likely manifold, and would exceed the purpose of this review. It must suffice to point out that, for example, endothelial expression of P-selectin is stimulated by most of the classic triggers of PH in animal models, including monocrotaline, hydrostatic stress, or hypoxia (modelling clinical PH of groups 2, 3, and—arguably in case of MCT—group 1, respectively). Similarly, environmental stresses, endothelial dysfunction, or injury will inevitably upregulate endothelial adhesion molecules and, thus, facilitate inflammatory cell infiltration into the vessel wall and perivascular space as well as trigger formation and release of pro-inflammatory cytokines. Finally, it is tempting to speculate that DNA damage, mosaic chromosomal abnormalities, and microsatellite instabilities as previously detected in pulmonary arterial endothelial cell cultures from PH lungs may facilitate expression of adhesion molecules and inflammatory cell recruitment, yet this concept remains to be experimentally tested.
Intriguingly, the recognition of an inflammatory and autoimmune component in PH sheds new light on the pivotal role of the endothelium in this disease that extends beyond classic concepts of endothelial damage or dysfunction, endothelial apoptosis and proliferation, or anti-endothelial antibodies, but points to a key role of the endothelium and its adhesion molecules as first line in the regulation of inflammatory and immune cell recruitment and infiltration (Fig. 4). While respective mechanistic studies seem long overdue, premature enthusiasm for potential translational benefits should be cautioned. Some 25 years ago, therapeutic targeting of adhesion molecules for the treatment or prevention of inflammatory disorders such as sepsis or the adult respiratory distress syndrome (ARDS) had already received a huge surge of attention both from the scientific community and industry; yet, to this date no approved therapy based on these concepts has materialized. That notwithstanding, a better understanding of the how, where, and when of immune cell adhesion and recruitment in PH may provide important novel insights into the mechanisms of disease, and—potentially—identify new therapeutic targets.

**Summary**

Intriguingly, the recognition of an inflammatory and autoimmune component in PH sheds new light on the pivotal role of the endothelium in this disease that extends beyond classic concepts of endothelial damage or dysfunction, endothelial apoptosis and proliferation, or anti-endothelial antibodies, but points to a key role of the endothelium and its adhesion molecules as first line in the regulation of inflammatory and immune cell recruitment and infiltration (Fig. 4). While respective mechanistic studies seem long overdue, premature enthusiasm for potential translational benefits should be cautioned. Some 25 years ago, therapeutic targeting of adhesion molecules for the treatment or prevention of inflammatory disorders such as sepsis or the adult respiratory distress syndrome (ARDS) had already received a huge surge of attention both from the scientific community and industry; yet, to this date no approved therapy based on these concepts has materialized. That notwithstanding, a better understanding of the how, where, and when of immune cell adhesion and recruitment in PH may provide important novel insights into the mechanisms of disease, and—potentially—identify new therapeutic targets.

**2017 Grover Conference Series**

This review article is part of the 2017 Grover Conference Series. The American Thoracic Society and the conference organizing committee gratefully acknowledge the educational grants provided for the support of this conference by Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., and United Therapeutics Corporation. Additionally, the American Thoracic Society is grateful for the support of the Grover Conference by the American Heart Association, the Cardiovascular Medical Research and Education Fund, and the National Institutes of Health.

**Conflict of interest**

The author(s) declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Arata Tabuchi [http://orcid.org/0000-0003-3543-176X](http://orcid.org/0000-0003-3543-176X)
References

1. Johnson SR and Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. *Eur Respir Rev* 2011; 20: 277–286.

2. Bigna JJ, Nansseu JR, Um LN, et al. Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis. *BMJ Open* 2016; 6: e011921.

3. Ehrlich P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. *Arch Anat Physiol* 1879; 3: 166–169.

4. Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. *Respir Res* 2011; 12: 60.

5. Heath D and Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. *J Clin Pathol* 1991; 44: 1003–1006.

6. Mitani Y, Ueda M, Maruyama K, et al. Mast cell chymase in pulmonary hypertension. *Thorax* 1999; 54: 88–90.

7. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 186: 897–908.

8. Heath D, Trueman T and Sukonthamarn P. Pulmonary mast cells in mitral stenosis. *Cardiovasc Res* 1969; 3: 467–471.

9. Heath D. Mast cells in the human lung at high altitude. *Int J Biometeorol* 1992; 36: 210–213.

10. Kay JM, Waymire JC and Grover RF. Lung mast cell hyperplasia and pulmonary histamine-forming capacity in hypoxic rats. *Am J Physiol* 1974; 226: 178–184.

11. Williams A, Heath D, Kay JM, et al. Lung mast cells in rats exposed to acute hypoxia, and chronic hypoxia with recovery. *Thorax* 1977; 32: 287–295.

12. Tucker A, McMurtry IF, Alexander AF, et al. Lung mast cell density and distribution in chronically hypoxic animals. *J Appl Physiol* 1977; 42: 174–178.

13. Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodeling in pulmonary hypertension. *Eur Respir J* 2011; 37: 1400–1410.

14. Kay JM, Gillund TD and Heath D. Mast cells in the lungs of rats fed on Crotalaria spectabilis seeds. *Am J Pathol* 1967; 51: 1031–1044.

15. Bartelds B, van Loon RL, Mohaupt S, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. *Chest* 2012; 141: 651–660.

16. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol* 1994; 144: 275–285.

17. Pinto RF, Higuchi ML and Aiello VD. Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. *Cardiovasc Pathol* 2004; 13: 268–275.

18. Minamino T, Christou H, Hsieh CM, et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. *Proc Natl Acad Sci U S A* 2001; 98: 8798–8803.

19. Miyata M, Sakuma F, Yoshimura A, et al. Pulmonary hypertension in rats. 1. Role of bromodeoxyuridine-positive mononuclear cells and alveolar macrophages. *Int Arch Allergy Immunol* 1995; 108: 281–286.

20. Perros F, Dorfmuller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. *Eur Respir J* 2007; 29: 462–468.

21. Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evaluation of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. *Hum Pathol* 1997; 28: 434–442.

22. Voelkel NF and Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. *Eur Respir J* 1995; 5: 2129–2138.

23. Song Y, Coleman L, Shi J, et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. *Am J Physiol Heart Circ Physiol* 2008; 295: H677–H690.

24. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 185: 311–321.

25. Colvin KL, Cripe PJ, Ivy DD, et al. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. *Am J Respir Crit Care Med* 2013; 188: 1126–1136.

26. Breitling S, Hui Z, Zabini D, et al. The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 2017; 312: L710–L721.

27. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. *Proc Natl Acad Sci U S A* 2007; 104: 11418–11423.

28. Paulin R, Meloche J and Bonnet S. STAT3 signaling in pulmonary arterial hypertension. *JAKSTAT* 2012; 1: 223–233.

29. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med* 1995; 151: 1628–1631.

30. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation* 2010; 122: 920–927.

31. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med* 1995; 151: 1628–1631.

32. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation* 2010; 122: 920–927.

33. Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response. *J Exp Med* 2008; 205: 361–372.

34. Hecker M, Zaslona Z, Kwapiszewska G, et al. Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010; 182: 805–818.

35. Balabanian K, Foussat A, Dorfmuller P, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. *Eur J Breathe Ther* 2010; 182: 805–818.

36. Dorfmuller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2002; 165: 1419–1425.

37. Itoh T, Nagaya N, Isihashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2007; 29: 462–468.

38. Miyata M, Sakuma F, Yoshimura A, et al. Pulmonary hypertension in rats. 1. Role of bromodeoxyuridine-positive mononuclear cells and alveolar macrophages. *Int Arch Allergy Immunol* 1995; 108: 281–286.
pulmonary arterial hypertension. Respir Med 2006; 11: 158–163.

38. Sanchez O, Marcos E, Perros F, et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176: 1041–1047.

39. Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung 2010; 188: 191–197.

40. Meloche J, Lampron MC, Nadeau V, et al. Implication of inflammation and epigenetic readers in coronary artery remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2017; 37: 1513–1523.

41. Meloche J, Potus F, Vaillancourt M, et al. Bromodomain-containing protein 4: The epigenetic origin of pulmonary arterial hypertension. Circ Res 2015; 117: 525–535.

42. Paulin R, Sutendra G, Gurtu V, et al. A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 2015; 116: 56–69.

43. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236–244.

44. Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6.

45. Tian W, Jiang X, Sung YK, et al. Leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013; 5: 200ra117.

46. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157: 219–229.

47. Yokomizo T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J Biochem 2015; 157: 65–71.

48. Qian J, Tian W, Jiang X, et al. Leukotriene B4 activates pulmonary artery adventitial fibroblasts in pulmonary hypertension. Hypertension 2015; 66: 1227–1239.

49. Abdul-Salam VB, Paul GA, Ali JO, et al. Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 2006; 6: 2286–2294.

50. Zhang J, Zhang Y, Li N, et al. Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir Med 2009; 103: 1801–1806.

51. Bauer EM, Zheng H, Comhair S, et al. Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One 2011; 6: e28578.

52. Hawksworth OA, Li XX, Coulthard LG, et al. New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol 2017; 89: 36–43.

53. Morgan BP and Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015; 14: 857–877.

54. Mizuno S, Farkas L, Al HA, et al. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012; 47: 679–687.

55. Sayed BA, Christy A, Quirion MR, et al. The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 2008; 26: 705–739.

56. Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217: 65–78.

57. Kishimoto T and Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol 1988; 6: 485–512.

58. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: S60–S65.

59. Tanaka M and Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149: 39–52.

60. Salamon P, Shoham NG, Puxeddu I, et al. Human mast cells release oncostatin M on contact with activated T cells: possible biologic relevance. J Allergy Clin Immunol 2008; 121: 448–455.

61. Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008; 181: 7243–7253.

62. Weyd C, Bea F, Wijelath E, et al. Oncostatin M is elevated in the plasma of patients with pulmonary arterial hypertension, but not in patients with ischemic heart disease or dilated cardiomyopathy: Insight into mechanisms in vitro. Circulation 2011; 124: A13449.

63. Botelho FM, Rangel-Moreno J, Fritz D, et al. Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation. J Immunol 2013; 191: 1453–1464.

64. Bonnet S, Provencher S, Guignabert C, et al. Translating research into improved patient care in pulmonary arterial hypertension. Am J Respir Crit Care Med 2017; 195: 583–595.

65. Farha S, Sharp J, Asosining K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Palm Circ 2012; 2: 220–228.

66. Meloche J, Renard S, Provencher S, et al. Anti-inflammatory and immunosuppressive agents in PAH. Handb Exp Pharmacol 2013; 218: 437–476.

67. Miyata M, Sakuma F, Ito M, et al. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000; 121: 246–252.

68. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007; 175: 1280–1289.

69. Tamosiuniene R, Tian W, Dhillon G, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011; 109: 867–879.

70. Ray A, Basu S, Williams CB, et al. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol 2012; 188; 3188–3198.

71. Chen LC, Delgado JC, Jensen PE, et al. Direct expansion of human allospecific Foxp3+ CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol 2009; 183: 4094–4102.

72. Reichardt P, Dornbach B, Rong S, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007; 110: 1519–1529.

73. Shah S and Qiao L. Resting B cells expand a CD4+ CD25+ Foxp3+ Treg population via TGF-b3. Eur J Immunol 2008; 38: 2488–2498.
76. Zheng J, Liu Y, Lau YL, et al. CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4+ regulatory T cells. *Cell Mol Immunol* 2010; 7: 44–50.

77. Hoehlig K, Shen P, Lampropoulou V, et al. Activation of CD40/Foxp3+ regulatory T cells proceeds normally in the absence of B cells during EAE. *Eur J Immunol* 2012; 42: 1164–1173.

78. Marino E, Villanueva J, Walters S, et al. CD4+CD25+ T-cells control autoimmunity in the absence of B-cells. *Diabetes* 2009; 58: 1568–1577.

79. Yu S, Ellis JS, Dunn R, et al. Transient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults. *Int Immunol* 2012; 24: 233–242.

80. Stasi R, Cooper N, Del PG, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. *Science* 2003; 301: 1374–1377.

81. Casellas R, Shih TA, Kleinewietfeld M, et al. Contribution of receptor editing to the antibody repertoire. *Science* 2001; 291: 1541–1544.

82. Hofmann J, Greter M, Du PL, et al. B-cells need a proper house, whereas T-cells are happy in a cave: the dependence of lymphocytes on secondary lymphoid tissues during evolution. *Trends Immunol* 2010; 31: 144–153.

83. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 185: 311–321.

84. Chaissone NF and Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. *Chest* 2013; 144: 1346–1356.

85. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. *Chest* 2010; 138: 1383–1394.

86. Kobak S, Kalkan S, Kirilmaz B, et al. Pulmonary arterial hypertension in patients with primary Sjögren’s syndrome. *Autoimmune Dis* 2014; 2014: 710401.

87. Nakagawa N, Osanai S, Ide H, et al. Severe pulmonary hypertension associated with primary Sjogren’s syndrome. *Intern Med* 2003; 42: 1248–1252.

88. Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. *Semin Arthritis Rheum* 1984; 13: 349–359.

89. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. *J Rheumatol* 1996; 23: 286–290.

90. Rich S, Kieras K, Hart K, et al. Antinuclear antibodies in primary pulmonary hypertension. *J Am Cardiol* 1986; 8: 1307–1311.

91. Yanai-Landau H, Amital H, Bar-Dayan Y, et al. Autoimmune aspects of primary pulmonary hypertension. *Pathobiology* 1995; 63: 71–75.

92. Tambry MC, Humbert M, Guelpain P, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. *Eur Respir J* 2006; 28: 799–807.

93. Arends SJ, Damaoiseaux J, Duijvestijn A, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2010; 35: 923–925.

94. Tamby MC, Chanseau Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. *Thorax* 2005; 60: 765–772.

95. Morse JH, Antohi S, Kasturi K, et al. Fine specificity of antifibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. *Scand J Immunol* 2000; 51: 607–611.

96. Becker MO, Kill A, Kutsche M, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. *Am J Respir Crit Care Med* 2014; 190: 808–817.

97. Colvin KL, Cripe PJ, Ivy DD, et al. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. *Am J Respir Crit Care Med* 2013; 188: 1126–1136.

98. La Cava A. Putting together the autoimmunity puzzle. *J Clin Invest* 2015; 125: 2184–2186.

99. Warde mann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. *Science* 2003; 301: 1374–1377.

100. Casellas R, Shih TA, Kleinewietfeld M, et al. Contribution of receptor editing to the antibody repertoire. *Science* 2001; 291: 1541–1544.

101. Halverson R, Torres RM and Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. *Nat Immunol* 2004; 5: 645–650.

102. Huppen KL, Schram BR, Tze LE, et al. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. *J Immunol* 2005; 175: 909–916.

103. Liang Y, Pan HF and Ye DQ. Therapeutic potential of STAT4 in autoimmunity. *Expert Opin Ther Targets* 2014; 18: 945–960.

104. Ebihara S, Date F, Dong Y, et al. Interleukin-17 is a critical target for the treatment of ankylosing spondylitis and psoriasis-like dermatitis in mice. *Autoimmunity* 2015; 48: 259–266.

105. Cully M. Connective tissue diseases: HMGB1 helps elicit anti-dsDNA antibody production in SLE. *Nat Rev Rheumatol* 2013; 9: 321.

106. Nogueira-Machado JA and de Oliveira Volpe CM. HMGB-1 as a target for inflammation controlling. *Recent Pat Endocr Metab Immune Drug Discov* 2012; 6: 201–209.

107. Pan HF, Wu GC, Li WP, et al. High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus. *Mol Biol Rep* 2010; 37: 1191–1195.

108. Bauer EM, Shapiro R, Zheng H, et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. *Mol Med* 2012; 18: 1509–1518.

109. Zabini D, Crnkovic S, Xu H, et al. High-mobility group box-1 induces vascular remodelling processes via e-Jun activation. *J Cell Mol Med* 2015; 19: 1151–1161.

110. Sadamura-Takenaka Y, Ito T, Noma S, et al. HMGB1 promotes the development of pulmonary arterial hypertension in rats. *PLoS One* 2014; 9: e102482.

111. Yang PS, Kim DH, Lee YJ, et al. Glycyrrhizin, inhibitor of glycogen synthase kinase 3, is a novel therapeutic agent for pulmonary hypertension. *Intern Med* 2012; 51: 607–611.
in severe macrophage activation syndrome. *Mol Med* 2014; 20: 538–547.

113. El Kasmi KC, Pugliese SC, Riddle SR, et al. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. *J Immunol* 2014; 193: 597–609.

114. Sawada H, Saito T, Nickel NP, et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. *J Exp Med* 2014; 211: 263–280.

115. Tian W, Jiang X, Tamosiuniene R, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. *Sci Transl Med* 2013; 5: 200ra117.

116. Xi X, Liu S, Shi H, et al. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. *Cardiovasc Toxicol* 2014; 14: 368–378.

117. Vergadi E, Chang MS, Lee C, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. *Circulation* 2011; 123: 1986–1995.

118. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 186: 897–908.

119. Avalos AM, Kiefer K, Tian J, et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. *Autoimmunity* 2010; 43: 103–110.

120. McDonnell M, Liang Y, Noronha A, et al. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. *Inflamm Bowel Dis* 2011; 17: 298–307.

121. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol* 2007; 8: 487–496.

122. Wen Z, Xu L, Chen X, et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. *J Immunol* 2013; 190: 5411–5422.

123. Li JH, Zhao B, Zhu XH, et al. Blockade of extracellular HMGB1 suppresses xenoreactive B cell responses and delays acute vascular xenogenic rejection. *Am J Transplant* 2015; 15: 2062–2074.

124. Urbanovicvite V and Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. *J Intern Med* 2011; 270: 309–318.

125. Meloche J, Courchesne A, Barrier M, et al. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. *J Am Heart Assoc* 2013; 2: e005157.

126. Meloche J, Paulin R, Courboin L, A et al. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. *Arterioscler Thromb Vasc Biol* 2011; 31: 2114–2124.

127. Crossno JT Jr, Garat CV, Reusch JE, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. *Am J Physiol Lung Cell Mol Physiol* 2007; 292: L885–L897.

128. Davie NJ, Crossno JT Jr, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. *Am J Physiol Lung Cell Mol Physiol* 2004; 286: L668–L678.

129. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a macrophage/macrophage lineage. *Am J Pathol* 2006; 168: 659–669.

130. Pabst R and Tschernig T. Perivascular capillaries in the lung: an important but neglected vascular bed in immune reactions? *J Allergy Clin Immunol* 2002; 110: 209–214.

131. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* 2007; 7: 678–689.

132. Muller WA. How endothelial cells regulate transmigration of leukocytes in the inflammatory response. *Am J Pathol* 2014; 184: 886–896.

133. Kuebler WM. Selectins revisited: the emerging role of platelets in inflammatory lung disease. *J Clin Invest* 2006; 116: 3106–3108.

134. Sriramarao P, Anderson W, Wolitzky BA, et al. Mouse bone marrow-derived mast cells roll on P-selectin under conditions of flow in vivo. *Lab Invest* 1996; 74: 634–643.

135. Steegmaier M, Blanks JE, Borges E, et al. P-selectin glycoprotein ligand-1 mediates rolling of mouse bone marrow-derived mast cells on P-selectin but not efficiently on E-selectin. *Eur J Immunol* 1997; 27: 1339–1345.

136. Li X, Abdi K, Rawn J, et al. LFA-1 and L-selectin regulation of recirculating lymphocyte tethering and rolling on lung microvascular endothelium. *Am J Respir Cell Biol* 1996; 14: 398–406.

137. Schmidt EP, Kuebler WM, Lee WL, et al. Adhesion molecules: master controllers of the circulatory system. *Compr Physiol* 2016; 6: 945–973.

138. Sakamaki F, Koyanagi S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. *Circulation* 2000; 102: 2720–2725.

139. Semenov AV, Kogan-Ponomarev MI, Ruda MI, et al. [Soluble P-selectin-a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension]. *Ter Arkh* 2000; 72: 15–20.

140. Yaota N, Shirakawa R, Fukumoto Y, et al. Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. *Arterioscler Thromb Vasc Biol* 2014; 34: 2486–2494.

141. Li XF, Song CH, Sheng HZ, et al. P-selectin gene polymorphism associates with pulmonary hypertension in congenital heart disease. *Int J Clin Exp Pathol* 2015; 8: 7189–7195.

142. Al-Naamani N, Palevsky HI, Lederer DJ, et al. Prognostic significance of biomarkers in pulmonary arterial hypertension. *Am J Thorac Sci* 2016; 13: 25–30.

143. Richter MJ, Schermuly R, Seeger W, et al. Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy. *Palm Circ* 2016; 6: 516–523.

144. Lapa M, Acencio MM, Farias AQ, et al. Selectins and platelet-derived growth factor (PDGF) in schistosomiasis-associated pulmonary hypertension. *Lung* 2014; 192: 981–986.
145. Oguz MM, Oguz AD, Sanli C, et al. Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension. *Tex Heart Inst J* 2014; 41: 159–164.

146. Sungprem K, Khongphatthanayothin A, Kiettisanpipop P, et al. Serum level of soluble intercellular adhesion molecule-1 correlates with pulmonary arterial pressure in children with congenital heart disease. *Pediatr Cardiol* 2009; 30: 472–476.

147. Calvier L, Legchenko E, Grimm L, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. *Heart* 2016; 102: 390–396.

148. Zorzanelli L, Maeda N, Clave M, et al. Relation of cytokine profile to clinical and hemodynamic features in young patients with congenital heart disease and pulmonary hypertension. *Am J Cardiol* 2017; 119: 119–125.

149. Blair LA, Haven AK and Bauer NN. Circulating microparticles in severe pulmonary arterial hypertension increase intercellular adhesion molecule-1 expression selectively in pulmonary artery endothelium. *Respir Res* 2016; 17: 133.

150. McVey M, Tabuchi A and Kuebler WM. Microparticles and acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2012; 303: L364–L381.

151. Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. *Br J Haematol* 2005; 130: 943–953.

152. Klings ES, Anton BD, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. *Am J Hematol* 2008; 83: 547–553.

153. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. *Ann Rheum Dis* 2008; 67: 1121–1126.

154. Szulek R, Happe CM, Rol N, et al. Delayed microvascular shear adaptation in pulmonary arterial hypertension. role of platelet endothelial cell adhesion molecule-1 cleavage. *Am J Respir Crit Care Med* 2016; 193: 1410–1420.

155. Venethasamy L, Hautefort A, Tielmans B, et al. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. *Pflugers Arch* 2016; 468: 1969–1983.

156. Le Hiress M, Tu L, Ricard N, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension, role of the macrophage migration inhibitory factor/CD74 complex. *Am J Respir Crit Care Med* 2015; 192: 983–997.

157. Hironaka E, Hongo M, Sakai A, et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. *Cardiovasc Res* 2003; 60: 692–699.

158. Kuebler WM, Ying X, Singh B, et al. Pressure is proinflammatory in lung venular capillaries. *J Clin Invest* 1999; 104: 495–502.

159. Venethasamy L, Hautefort A, Tielmans B, et al. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. *Pflugers Arch* 2016; 468: 1969–1983.

160. Ranchoux B, Meloche J, Paulin R, et al. DNA damage and pulmonary hypertension. *Int J Mol Sci* 2016; 17: E990.

161. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. *Circ Res* 2001; 88: E2–E11.

162. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. *Thorax* 2005; 60: 765–772.